AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” oregon the “Company”) officially launches its commercial-stage enterprise, seeking to grow diligent entree to medicines for uncommon diseases successful Europe portion unlocking gross and maturation imaginable for emerging research-based biopharmaceutical originators. Avanzanite, a afloat authorized distributor of medicinal products, partners with these biopharmaceutical collaborators done flexible, bespoke licensing and organisation partnerships crossed Europe. The Company’s caller concern exemplary enables the planetary commercialization of promising medicines and addresses the unsustainable inequities successful entree to innovative orphan drugs crossed Europe.
Avanzanite was established to code a captious marketplace request successful the European orphan cause scenery owed to the complexity and outgo of streamlining concern operations crossed 30+ countries fixed a constricted fig of patients and an progressively challenging marketplace entree environment. In fact, astir European launches of orphan drugs – immoderate experts assertion arsenic precocious arsenic 80% – neglect to conscionable their commercialized and gross goals and bash not scope patients successful need. The effect of these unsocial marketplace dynamics leaves emerging biopharmaceutical companies unmotivated oregon ill-equipped to found European operations oregon participate definite countries. As a result, determination are an expanding fig of biopharmaceutical companies either opting not to motorboat their caller orphan medicines successful Europe oregon exiting the marketplace altogether. These dynamics are peculiarly damaging to emerging biopharmaceutical originators that are the driving unit of planetary pharmaceutical innovation, particularly for uncommon diseases. Ultimately, the patients are the ones paying the terms by missing retired connected promising therapies.
Avanzanite’s Founder and CEO, Adam Plich, stated, “We are providing a market-driven solution for the contented of entree to orphan medicines successful Europe.”
“Our inspiration and the archetypal validation of our unsocial concern exemplary stems from our collaboration and an exclusive licence statement with SIFI S.p.A. (“SIFI”), a starring planetary ophthalmic institution headquartered successful Italy.” Mr. Plich continued, “SIFI partnered with Avanzanite to commercialize and administer its investigational ultra-orphan medicine for the attraction of Acanthamoeba Keratitis (AK) – a devastating, highly resistant oculus corruption that accounts for 50% of blindness among interaction lens users – crossed 26 countries wrong the European Economic Area and Switzerland.” After much than 15 years of probe & improvement efforts, the European Medicines Agency (“EMA”) is presently reviewing the merchandise for selling approval.
“When evaluating commercialization options for our orphan medicine successful aggregate European territories,” stated Fabrizio Chines, SIFI Chairman and CEO. “Avanzanite made a compelling lawsuit arsenic to wherefore it would beryllium champion positioned to commercialize and, successful fact, supply the broadest marketplace entree done its unsocial concern model.” Mr. Chines continued, "Mr. Plich and his squad demonstrated an awesome way grounds of managing the complexities of merchandise launches crossed the fragmented European marketplace, peculiarly regarding pricing & reimbursement, doc engagement and method operations.”
Mr. Plich has a proven way grounds of palmy merchandise launches successful Europe. Most recently, helium founded and led a boutique advisory steadfast supporting U.S. and European biopharmaceutical companies connected firm strategy and merchandise launch. Previously, helium served arsenic a Vice President astatine Teva Pharmaceuticals wherever helium led each pricing and marketplace entree activities successful the European marketplace. Anant Murthy, Co-Founder and Board Advisor, besides brings a demonstrated way grounds of palmy orphan medicine launches and is presently the EMEA General Manager astatine Argenx. Previously, Murthy was a Vice President astatine Alnylam wherever helium led pricing & marketplace entree for EMEA & Canada and was the General Manager of mid-size EU markets and Canada. Additionally, Avanzanite benefits from the heavy expertise of its Advisory Board: Dawn Sherman, CEO of LabConnect; Daniel A. de Boer, CEO astatine ProQR; and Leopoldo Zambeletti, an autarkic healthcare firm concern advisor. The Company has besides established captious infrastructure and hired cardinal leaders crossed commercialization and method operations areas.
Avanzanite is advancing discussions with respective biopharmaceutical companies seeking to participate the European marketplace successful bid to grow its portfolio breadth. Given the precocious fig of investigational drugs successful improvement for orphan diseases, Avanzanite envisions important accidental to grow diligent entree and optimize worth instauration for originators. Avanzanite sees its near-term maturation accidental successful late-stage oregon approved ultra- oregon different overlooked orphan medicines. Mr. Plich concluded, “We’ve cracked the codification successful deciphering this tricky landscape, and now, with our archetypal strategical concern with SIFI, we are acceptable to instrumentality our transformational exemplary to the adjacent level by bringing caller medicines to patients with uncommon diseases.”
ABOUT AVANZANITE BIOSCIENCE: Founded successful 2021, by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is connected a ngo to redefine the commercialization of orphan medicines to amended diligent entree crossed Europe and beyond. Derived from the connection ‘Tanzanite’ – 1 of the rarest and astir underappreciated gemstones connected world – Avanzanite was formed to capitalize connected 2 superior objectives, 1 economic, and 1 humanitarian. The economical extremity is to connection end-to-end commercialization and organisation concern with research-based biopharmaceutical originators to unlock the afloat worth of their orphan medicines successful European markets; this is the unsocial expertise and halfway competency of the Avanzanite squad done its decades of operating acquisition navigating this area. Equally important, the Company's humanitarian extremity stems from our committedness to enabling entree to caller medicines for patients who endure from orphan diseases careless of wherever successful Europe they live. Avanzanite is afloat authorized to administer medicinal products passim the European Economic Area.
English (US)